Indications -- Cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (392)	6/5/2003 2:41:10 PM
From: Icebrg	Read Replies (1) of 1840

Hormonal and Targeted Therapies in Breast Cancer: An interview with Harold J. Burstein, MD, PhD Disclosures Mary Beth Nierengarten, MA Tamoxifen remains the most commonly used hormonal agent for the treatment of advanced breast cancer, as adjuvant therapy for early disease, and as preventive therapy for patients at high risk of disease development. However, newer hormonal agents are contesting the superiority of tamoxifen and competing for attention. In an interview with Medscape, Dr. Harold J. Burstein, Assistant Professor of Medicine at Dana-Farber Cancer Institute in Boston, Massachusetts, discussed the current data being presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO) on hormonal and targeted therapies for breast cancer... medscape.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next